IRIS Institutional Research Information System - OPENBS Open Archive UniBS

POLVERELLI, NICOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.255
AS - Asia 3.939
EU - Europa 2.485
SA - Sud America 890
AF - Africa 106
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 2
Totale 12.684
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.108
SG - Singapore 1.640
CN - Cina 943
BR - Brasile 735
IT - Italia 645
HK - Hong Kong 497
DE - Germania 350
VN - Vietnam 314
FI - Finlandia 224
UA - Ucraina 221
FR - Francia 217
PL - Polonia 184
TR - Turchia 161
RU - Federazione Russa 157
GB - Regno Unito 156
IN - India 105
IE - Irlanda 72
CA - Canada 69
BD - Bangladesh 59
AR - Argentina 54
SE - Svezia 49
ZA - Sudafrica 48
MX - Messico 43
CZ - Repubblica Ceca 40
NL - Olanda 40
IQ - Iraq 39
JP - Giappone 35
ES - Italia 27
AT - Austria 26
EC - Ecuador 20
CO - Colombia 19
BE - Belgio 17
JO - Giordania 16
VE - Venezuela 16
PY - Paraguay 14
ID - Indonesia 13
MA - Marocco 12
PE - Perù 12
UZ - Uzbekistan 11
SA - Arabia Saudita 10
TH - Thailandia 10
AE - Emirati Arabi Uniti 9
EG - Egitto 9
ET - Etiopia 8
IL - Israele 8
PH - Filippine 8
PK - Pakistan 8
TN - Tunisia 8
AZ - Azerbaigian 7
CL - Cile 7
CR - Costa Rica 7
GR - Grecia 7
LT - Lituania 7
MY - Malesia 7
PA - Panama 7
PT - Portogallo 7
UY - Uruguay 7
AU - Australia 6
BO - Bolivia 6
DZ - Algeria 6
HN - Honduras 6
KE - Kenya 6
KG - Kirghizistan 6
BG - Bulgaria 5
IR - Iran 5
JM - Giamaica 5
LV - Lettonia 5
OM - Oman 5
PS - Palestinian Territory 5
LK - Sri Lanka 4
CH - Svizzera 3
HU - Ungheria 3
SN - Senegal 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
AL - Albania 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
EE - Estonia 2
EU - Europa 2
GA - Gabon 2
GT - Guatemala 2
HR - Croazia 2
IM - Isola di Man 2
KR - Corea 2
KZ - Kazakistan 2
MD - Moldavia 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
AM - Armenia 1
AO - Angola 1
BH - Bahrain 1
CY - Cipro 1
GE - Georgia 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
Totale 12.677
Salva come PNG Salva come JPEG
Città #
Singapore 891
Ashburn 584
Hong Kong 495
San Jose 403
Fairfield 376
Beijing 281
The Dalles 227
New York 224
Chandler 195
Woodbridge 194
Warsaw 172
Seattle 171
Helsinki 160
Munich 160
Jacksonville 159
Dallas 153
Los Angeles 151
Wilmington 143
Cambridge 138
Brescia 129
Houston 125
Lauterbourg 123
Ann Arbor 121
Istanbul 116
Princeton 115
Ho Chi Minh City 97
Des Moines 79
São Paulo 79
Hanoi 70
Dublin 69
Shanghai 66
Boardman 61
Moscow 60
Chicago 57
Redondo Beach 57
San Francisco 56
Buffalo 51
Santa Clara 48
Turku 47
Orem 46
Milan 45
Romola 41
London 36
Council Bluffs 32
Johannesburg 32
Tokyo 32
Brno 30
Montreal 27
Nuremberg 27
Frankfurt am Main 26
Brooklyn 24
Rome 24
Atlanta 22
Denver 22
Belo Horizonte 21
Nanjing 20
Rio de Janeiro 20
Toronto 20
Pune 19
San Diego 19
Boston 18
Charlotte 18
Chennai 18
Manchester 18
Amsterdam 17
Brussels 17
Da Nang 17
Jinan 17
Stockholm 17
Amman 16
Haiphong 16
Guangzhou 15
Brasília 14
Tianjin 14
Baghdad 13
Dearborn 13
Kyiv 13
Barlassina 12
Biên Hòa 12
Curitiba 12
Lappeenranta 12
Paris 12
Poplar 12
Florence 11
Mexico City 11
Mumbai 11
Shenyang 11
Changsha 10
Genoa 10
Phoenix 10
Tashkent 10
Turin 10
Verona 10
Wroclaw 10
Ankara 9
Bologna 9
Bosio 9
Dhaka 9
Hangzhou 9
Hải Dương 9
Totale 7.999
Salva come PNG Salva come JPEG
Nome #
BACTERIAL BLOOD STREAM INFECTIONS NEGATIVELY IMPACT ON OUTCOME OF PATIENTS TREATED WITH ALLOGENEIC STEM CELL TRANSPLANTATION: 6 YEARS SINGLE-CENTRE EXPERIENCE 291
Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia 203
Comparative study on ATG-thymoglobulin versus ATG-fresenius for the graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation from matched unrelated donor: a single-centre experience over the contemporary years 198
Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF) 172
Multidimensional Geriatric Assessment for Elderly Patients (≥60 years) Submitted for Allogeneic Stem Cell Transplantation. a French (Paris) - Italian (Brescia) 10-Years Experience on 228 Patients 167
Advances in CMV Management: A Single Center Real-Life Experience 167
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 166
Clinical Care of Hematological Patients in a Bone Marrow Transplant Unit: Do Human Resources Influence Infection Incidence? 164
Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms 162
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 159
High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review 157
CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS 153
Identification of a Novel Mutation Predisposing to Familial AML and MDS Syndrome By a NGS Approach 153
RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients? 152
Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner? 148
First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response 148
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 147
CT-290: Clinical Frailty Scale as a Novel Tool to Evaluate Patients’ Eligibility for Allogeneic Stem Cell Transplant: A Single-Center Experience on 234 Patients >50 Years Old 144
ANTI-CMV Immunoglobulins in Association with ANTI-CMV Drugs in Patients with Hematological Malignancies Submitted to Allogeneic STEM CELL Transplantation: A MULTI-Center Retrospective Experience 140
Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients 137
Comparative Study on Fresenius-ATG Versus Thymoglobuline-ATG for the Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation from Matched Unrelated Donor: A Single Center Experience on 76 Patients 136
Digital PCR (Dpcr) a Step Forward to Detection and Quantification of Minimal Residual Disease (MRD) in Ph+/BCR-ABL1 Chronic Myeloid Leukemia (CML) 135
ETV6: A Candidate Gene for Predisposition to “Blend Pedigrees”? A Case Report from the NEXT-Famly Clinical Trial 133
IN VIVO STUDY (MYCEC0617) OF CD34+-HSC AND CEC MUTATIONAL PROFILE FOR INVESTIGATING CELL ORIGIN AND PATHOGENESIS OF PRIMARY MYELOFIBROSIS (PMF) 130
Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations 129
Case Report: Late Onset of Myelodysplastic Syndrome From Donor Progenitor Cells After Allogeneic Stem Cell Transplantation. Which Lessons Can We Draw From the Reported Case? 128
Allogeneic transplantation for patient with myelodisplastic sindromes: a single centre experience 127
Sequential monitoring of lymphocyte subsets and of T-and-B cell neogenesis indexes to identify time-varying immunologic profiles in relation to graft-versus-host disease and relapse after allogeneic stem cell transplantation 126
P1450: AUTOLOGOUS STEM CELL TRANSPLANTATION INDUCES HIGHER LEVEL OF EXHAUSTED T-CELLS IN DLBCL PATIENTS BEFORE LEUKAPHERESIS FOR CAR-T CELL THERAPY 125
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 125
ANTI-CMV IMMUNOGLOBULINS IN ASSOCIATION WITH ANTI-CMV DRUGS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES SUBMITTED TO ALLOGENEIC STEM CELL TRANSPLANTATION: A MULTI-CENTRE RETROSPECTIVE EXPERIENCE 125
DIGITAL PCR IN PH plus CHRONIC MYELOID LEUKEMIA PATIENTS FOR RECOGNITION OF "STABLE" DEEP MOLECULAR RESPONSE AND IDENTIFICATION OF BEST CANDIDATES TO TKI DISCONTINUATION 125
Safety and Efficacy of ATG-based GvHD prophylaxis in allogeneic stem cell transplantation for acute leukemia and myelodysplastic syndrome: a single center experience 123
Liposomal doxorubicin for the treatment of iatrogenic kaposi sarcoma following hematopoietic stem cell transplantation 123
Successful hematopoietic stem cell transplantation for complete CTLA-4 haploinsufficiency due to a de novo monoallelic 2q33.2-2q33.3 deletion 122
PB2209: HIGH RISK MYELODYSPLASTIC SYNDROME DEVELOPING IN A PATIENT AFTER CHIMERIC ANTIGEN RECEPTOR (CAR) T- CELL THERAPY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA 121
Feasibility of Leukemia-Derived Exosome Enrichment and Co-isolated dsDNA Sequencing in Acute Myeloid Leukemia Patients: A Proof of Concept for New Leukemia Biomarkers Detection 120
OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY 120
Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey) 120
Comparative monitoring of deep molecular response (DMR) by RT-quantitative (RT-qPCR) and digital PCR (dPCR) in Ph+ Chronic Myeloid Leukemia (CML) patients treated with TKIs for recognition of stable deep molecular response (DMR) and identification of best candidates to TKIs treatment discontinuation. 119
Autologous Stem Cell Transplantation before Lymphocyte Apheresis for CAR-T Cells Therapy Negatively Impacts on T-Cells Fitness and NK Cell Levels in DLBCL Patients 118
3-YEARS and Beyond Study Completion Results of the Otpkima Randomized Clinical Trial in Elderly CML Patients 118
Post Induction and Post Consolidation Measurable/Minimal Residual Disease Predict Relapse in NPM-1 Positive AML. Outcome of Treatment Relapse. a Single Center Experience 117
Nutritional intervention with TGF-beta enriched food for special medical purposes (TGF-FSMP) is associated with a reduction of malnutrition, acute GVHD, pneumonia and may improve overall survival in patients undergoing allogeneic hematopoietic stem transplantation 115
A Systematic Review of the Literature and Perspectives on the Role of Biomarkers in the Management of Malnutrition After Allogeneic Hematopoietic Stem Cell Transplantation 115
Pre-Emptive Donor Lymphocyte Infusion As Optimal Treatment for Relapsed Acute Myeloid Leukemias and Myelodysplastic Syndromes Following Allogeneic Stem Cell Transplantation: Insights from a French-Italian Study on 134 Patients 114
EXTRACORPOREAL PHOTOPHERESIS FOR THE TREATEMENT OF ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE: A RETROSPECTIVE MULTICENTRIC ANALYSIS ON 94 PATIENTS. 113
Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial 111
Results of an Innovative Program for Surveillance, Prophylaxis, and Treatment of Infectious Complications Following Allogeneic Stem Cell Transplantation in Hematological Malignancies (BATMO Protocol) 110
EXTRACORPOREAL PHOTOPHERESIS (ECP) FOR TREATEMENT OF ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE: AN ITALIAN MULTICENTRIC RETROSPECTIVE ANALYSIS ON 94 PATIENTS ON BEHALF OF THE GRUPPO ITALIANO TRAPIANTO DI MIDOLLO OSSEO (GITMO) 109
Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis 109
Potentiality of Bone Marrow-Derived Mesenchymal Stromal Cells (BM-MSCs) to Differentiate into the Osteogenic Lineage in in Vitro Model of Tissue Regeneration 107
PS1540 MULTIPARAMETRIC PREDICTIVE SCORE FOR GRAFT VERSUS HOST DISEASE (GVHD) IN PATIENTS SUBMITTED TO ALLOGENEIC STEM CELLS TRANSPLANTATION (SCT) 107
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 105
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 105
Timely Leukapheresis May Interfere with the “Fitness” of Lymphocytes Collected for CAR-T Treatment in High Risk DLBCL Patients 103
Correlation between BCR::ABL1 Transcript LEVEL in Circulating Extracellular Vesicles and BOTH the Molecular Response and the Ongoing Therapy: A Study on Adult CML Patients 103
Severe Acute Respiratory Syndrome Coronavirus-2 Pandemia: Facts and Perspectives in a Bone Marrow Transplant Unit 102
Exosomes in Chronic Myeloid Leukemia: Are We Reading a New Reliable Message? 101
Malnutrition Prevention after Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT): A Prospective Explorative Interventional Study with an Oral Polymeric Formulation Enriched with Transforming Growth Factor Beta 2 (TGF-β2) 99
Evaluation of Circulating Endothelial Cells (CECs) As Marker of Endothelial Damage in Allo-Transplanted Patients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS): The Cecinvod Study 99
Incidence and Outcome of Bacterial Blood Stream Infections in Allotransplanted Patients: Rethinking the Role of Fluoroquinolone Prophylaxis 99
Favourable/Intermediate ELN-Risk Acute Myeloid Leukemia to Transplant or Not to Transplant First-Line? 99
dsDNA from extracellular vesicles (EVs) in adult AML 99
Bone marrow CD34+ molecular chimerism as an early predictor of relapse after allogeneic stem cell transplantation in patients with acute myeloid leukemia 98
Successful CAR-T cell therapy in a refractory MCL patient with bacterial, fungal and COVID-19 infection: a case report 96
CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation 96
PF404 TUMOR-DERIVED EXOSOMES MAY BE USED AS NEW INFORMATIVE TOOL FOR THE DETECTION OF BONE MARROW RESIDUAL CML LEUKEMIC CELLS ACTIVITY 96
Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT) 92
How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation 92
PF688 JAK2 ALLELIC RATIO IMPACTS ON VASCULAR EVENT IN MYELOFIBROSIS BY INCREASING THE RISK OF THROMBOSIS. A SINGLE CENTER EXPERIENCE ON 150 PATIENTS 91
Donor Lymphocyte Infusion in the Treatment of Post-Transplant Relapse of Acute Myeloid Leukemias and Myelodysplastic Syndromes Significantly Improves Overall Survival: A French–Italian Experience of 134 Patients 90
Outcome of Patients With Acute Myeloid Leukemias or Myelodysplastic Syndromes After Relapsing From Allogeneic Stem Cell Transplantation: The GITMO AML/MDS‐Relapse Registry Study 87
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study 86
Minimal residual disease monitoring in acute myeloid leukaemia: are we ready to move from bone marrow to peripheral blood? 84
PB1959: BCR::ABL1 TRANSCRIPT IN SMALL EXTRACELLULAR VESICLES ISOLATED IN ADULT CHRONIC MYELOID LEUKEMIA PATIENTS CORRELATES WITH MOLECULAR RESPONSE LEVEL AND THE ONGOING THERAPY 82
S882 OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY 80
Correction: CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation (Bone Marrow Transplantation, (2023), 10.1038/s41409-023-02124-y) 77
Association of essential thrombocythemia and non-Hodgkin lymphoma: A single-centre experience 76
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 75
Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study 72
Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party 71
Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: Possible role of MPL polymorphisms 71
MALNUTRITION AND GVHD IN ALLOGENIC BONE MARROW TRANSPLANTATION: A PROSPECTIVE STUDY 69
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera 69
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 68
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis 67
A case report of acute myeloid leukemia and neurofibromatosis 1 63
Long-term follow-up of essential thrombocythemia in young adults: Treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients 62
Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT 62
Bleeding in essential thrombocythaemia: A retrospective analysis on 565 patients 61
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 61
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT 61
Digital PCR as a New Method for Minimal Residual Disease Monitoring and Treatment Free Remission Management in Chronic Myeloid Leukemia Patients: Is It Reliable? 60
Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis 59
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis 59
Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease 59
Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study 59
JAK2V617F mutation in essential thrombocythemia: Correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients 58
Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: An in vitro study 56
Totale 11.082
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.195
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.195
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021289 0 0 0 0 0 0 0 0 0 155 75 59
2021/2022559 48 33 18 42 18 45 27 49 30 87 33 129
2022/2023683 79 19 30 52 55 136 3 129 82 17 43 38
2023/20241.196 51 26 96 62 72 221 50 46 287 14 17 254
2024/20252.877 39 56 82 334 291 240 175 116 399 236 522 387
2025/20265.464 508 618 495 919 566 404 830 271 380 473 0 0
Totale 12.881